Fig. 1From: Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseasesStudy Flow chart. Abbreviation: Study group A-M adalimumab and methotrexate co-treatment, Study group A adalimumab alone, Cmax maximum adalimumab concentration collected 1 to 9Â days after adalimumab administration, Cmin minimum adalimumab concentration collected 10 to 14Â days after adalimumab administration, MTX methotrexateBack to article page